603368 柳药集团
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)5.58212.00513.50012.27610.680
总资产报酬率 ROA (%)2.0234.1274.3834.0693.675
投入资产回报率 ROIC (%)2.6695.6255.9755.6015.071

边际利润分析
销售毛利率 (%)11.07011.36611.88911.50511.416
营业利润率 (%)4.9034.7385.0154.6724.395
息税前利润/营业总收入 (%)5.9095.8466.2125.8295.596
净利润/营业总收入 (%)4.2564.0964.3563.9843.741

收益指标分析
经营活动净收益/利润总额(%)102.617101.247104.038104.008102.636
价值变动净收益/利润总额(%)-0.000-0.009-0.0680.8320.264
营业外收支净额/利润总额(%)-1.202-0.046-0.0290.0380.211

偿债能力分析
流动比率 (X)1.6261.5701.4911.4891.551
速动比率 (X)1.3521.3471.2921.2621.342
资产负债率 (%)61.82862.68364.96165.79163.424
带息债务/全部投入资本 (%)50.95647.51952.51452.37048.575
股东权益/带息债务 (%)90.930104.03284.17184.62597.040
股东权益/负债合计 (%)59.28257.18950.53348.76054.229
利息保障倍数 (X)5.5525.2655.1835.0444.697

营运能力分析
应收账款周转天数 (天)187.443178.818165.680151.143143.390
存货周转天数 (天)56.55547.44346.80645.55739.983